Expression and clinical significance of CREB1 and CREB3 in gastric cancer and precancerous lesions

Abstract

Abstract Background: To investigate the expression and clinical significance of cyclic adenosine monophosphate responsive CREB1 and CREB3 in gastric cancer and precancerous lesions. Methods and Results: All data was collected in June 2021 to April 2022 from the second affiliated hospital of Baotou medical college with archive wax block of 40 cases of chronic superficial gastritis. The expressions of CREB1 and CREB3 in different gastric tissues were detected by Western blot. Kaplan-meier Plotter was used to analyze the correlation between the expression of CREB1 and CREB3 and overall survival and progression-free survival of gastric cancer patients. The positions of CREB1 and CREB3 in the signaling pathway and their related upstream and downstream genes were analyzed using STRING database. (1) Immunohistochemistry staining results showed the positive expression rates of CREB1 and CREB3 in gastric cancer group significantly higher than those in chronic atrophic gastritis with intestinal metaplasia, but there was no significant difference between them and dysplasia group. Clinicopathological parameters analysis showed that the expression levels of both were correlated with depth of invasion, TNM stage, vascular invasion and lymph node metastasis. (2) Western blot results indicated that the protein expression of CREB1 and CREB3 increased successively in chronic superficial gastritis, chronic atrophic gastritis with intestinal metaplasia, and gastric cancer, and the difference was statistically significant. Conclusion: CREB1 and CREB3 may be related to the occurrence, development and metastasis of gastric cancer, and the high expression of CREB1 and CREB3 may be related to the poor prognosis of gastric cancer patients.